Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Flu-M vs. Ultrix in Volunteers Aged Over 60 Years
NCT05089123Phase 3Completed
- Sponsor
- Saint Petersburg Scientific Research Institute of Vaccines and Serums
- Start
- Mar 2020
- Primary completion
- May 2020
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen in influenza, sponsored by Saint Petersburg Scientific Research Institute of Vaccines and Serums. Started Mar 2020; status: completed.
02
Drugs
Influenza A virus A/Victoria/2570/2019 IVR-215 (H1N1) antigen
03
Conditions
influenza
Beyond the preview
Go deeper on NCT05089123.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05089123.